Vida Ventures Advisors is an investment fund managing more than $91.4 billion ran by Jean-philippe Kouakou-zebouah. There are currently 5 companies in Kouakou-zebouah’s portfolio. The largest investments include Centessa Pharmaceuticals Plc and Kyverna Therapeutics, Inc., together worth $69.4 billion.
As of 3rd July 2024, Vida Ventures Advisors’s top holding is 3,931,818 shares of Centessa Pharmaceuticals Plc currently worth over $35.5 billion and making up 38.8% of the portfolio value.
In addition, the fund holds 4,523,924 shares of Kyverna Therapeutics, Inc. worth $33.9 billion.
The third-largest holding is Dyne Therapeutics worth $14.4 billion and the next is Allogene Therapeutics Inc worth $4.19 billion, with 1,798,163 shares owned.
Currently, Vida Ventures Advisors's portfolio is worth at least $91.4 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Vida Ventures Advisors office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Jean-philippe Kouakou-zebouah serves as the Chief Financial Officer at Vida Ventures Advisors.
The two most similar investment funds to Vida Ventures Advisors are Hudson Portfolio Management and Fox , Inc. They manage $91.4 billion and $91.5 billion respectively.
Vida Ventures Advisors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 24.1% of
the total portfolio value.
The fund focuses on investments in the United States as
60.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $596 million.
These positions were updated on July 10th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Centessa Pharmaceuticals Plc |
No change
3,931,818
|
$35,504,317,000 | 38.83% |
| Kyverna Therapeutics, Inc. |
No change
4,523,924
|
$33,929,430,000 | 37.11% |
| Dyne Therapeutics, Inc. |
No change
407,499
|
$14,380,640,000 | 15.73% |
| Allogene Therapeutics Inc |
No change
1,798,163
|
$4,189,720,000 | 4.58% |
| Kronos Bio, Inc. |
No change
2,765,314
|
$3,428,989,000 | 3.75% |
| No transactions found | |||
| Showing first 500 out of 5 holdings | |||